4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Chondrosarcoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Chondrosarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 43 ongoing clinical trials involving Chondrosarcoma
Of the 43 trials,20 trials are in Phase II
Furthermore, 12 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Chondrosarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Chondrosarcoma, an Oncology indication. The largest number of ongoing clinical trials for Chondrosarcoma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions involved in Chondrosarcoma-related drug trials.

Memorial Sloan Kettering Cancer Center: The leading ongoing Chondrosarcoma-related clinical trial sponsor

Memorial Sloan Kettering Cancer Center, the US-based government institute, is the top sponsor for Chondrosarcoma-related ongoing clinical trials.

Epizyme Inc, University of Texas MD Anderson Cancer Center, Centre Leon Berard, UNICANCER Group, and Inhibrx Inc are a few other notable sponsors involved in Chondrosarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Chondrosarcoma

Ifosfamide (Ifoma) is the sole key marketed drug involving Chondrosarcoma.

Ifosfamide (Ifoma) is a synthetic analog of cyclophosphamide that belongs to antineoplastic, immunosuppressive agent. It functions via the DNA Synthesis Inhibitor mechanism of action. It is formulated as a powder for solution for intravenous route of administration. Ifosfamide is indicated for the treatment of bronchial carcinoma, ovarian carcinoma, breast carcinoma, testicular tumors, pancreatic carcinoma, malignant lymphoma, osteosarcoma, sarcoma of soft tissue, rhabdomyoma, cervix carcinoma, head and neck carcinoma, Ewing’s sarcoma. Ifosfamide was first approved in 1996 and is marketed in South Korea by Guju Pharm Co Ltd.

Explore the latest trends and actionable insights on the Chondrosarcoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Chondrosarcoma Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store